扎鲁司特治疗儿童咳嗽变异性哮喘疗效观察

目的 :观察扎鲁司特治疗儿童咳嗽变异性哮喘的疗效。方法 :90例咳嗽变异性哮喘儿童随机分为扎鲁司特治疗组 5 5例 ,对照组 35例。对治疗组使用扎鲁司特 6～ 12岁每次 10mg,～ 14岁每次 2 0mg ,每日二次 ,连用 4周 ;对照组用沙丁胺醇。观察两组患儿咳嗽情况。结果 :治疗组与对照组显效率分别为 40 %和 2 0 % (χ2 =3 91,P <0 0 5 ) ,总有效率分别为 90 9%和 6 0 % (χ2 =12 2 7,P <0 0 0 1)。结论 :扎鲁司特治疗儿童咳嗽变异性哮喘疗效明显     

卡维地洛治疗轻、中度高血压病72例

目的 :观察国产卡维地洛治疗轻、中度高血压病的临床疗效和安全性并与美托洛尔做对照比较。方法 :14 4例轻、中度高血压病人随机分为卡维地洛组与美托洛尔组各 72例 ,分别用卡维地洛 10～ 2 0mg ,po ,bid与美托洛尔 2 5～ 5 0mg ,po ,bid ,共 6wk。结果 :卡维地洛组总有效率 81% ,显效率4 4% ;美托洛尔组总有效率 72 % ,显效率 36 % ;2组疗效比较差异无显著意义 (P >0 .0 5 )。 2组wk 6末心率与治疗前相比均有显著差异 (P <0 .0 5 )。卡维地洛组wk 6末动态血压监测的SBP和DBP的T/P值分别为 6 1.2 %和 5 0 .3%。wk 6末卡维地洛组尿微量蛋白降低明显 ,与治疗前相比有显著差异 ,与wk 6末美托洛尔组相比亦有非常显著差异(P <0 .0 1)。 2组不良反应的发生率分别为 19%及 18% ,均较轻微。结论 :国产卡维地洛治疗轻、中度高血压病有效、安全、并对肾脏有很好的保护作用     

甲硝唑凝胶治疗中、重度酒渣鼻随机双盲、安慰剂对照临床试验

目的 :评价 0 .75 %甲硝唑凝胶治疗中、重度酒渣鼻的临床疗效和安全性。方法 :采用随机、双盲、安慰剂对照方法 ;病人在皮损区域局部外用0 .75 %甲硝唑凝胶或安慰剂 ,每日 2次 ,疗程 12wk。结果 :可分析病例 6 2例 ,其中甲硝唑组 31例 ,安慰剂组 31例。治疗后炎性损害百分数 ,甲硝唑组与安慰剂组在wk 4时分别为 (2 9± 38) %vs (1±83) % (P >0 .0 5 ) ,wk 8时为 (49± 5 1) %vs (3±83) % (P <0 .0 5 ) ,wk 12时为 (5 6± 4 2 ) %vs (2 1± 4 8) % (P <0 .0 1)。wk 12时红斑消失甲硝唑组和安慰剂组分别为 8%和 4 % ,2组比较差异无显著意义 (P >0 .0 5 )。用药后局部刺激反应 ,甲硝唑组为 2 9% ,安慰剂组为 2 3% ,均为轻、中度 ,2组比较差异无显著意义 (P >0 .0 5 )。结论 :0 .75 %甲硝唑凝胶治疗中、重度酒渣鼻的疗效肯定 ,安全性高     

国产与进口特布他林注射液的平喘疗效比较

目的 :比较国产与进口特布他林注射液对支气管哮喘 (哮喘 )和喘息性支气管炎 (喘支炎 )的平喘效果。方法 :10 0例中度喘息发作的哮喘和喘支炎病人 ,采用非盲法序贯随机对照法分为国产组和进口组各 4 0例 ,开放组 2 0例分别给予国产与进口特布他林注射液 0 .2 5mg +氯化钠注射液 10 0mL静脉滴注 10 0min ,tid× 3d。治疗前后分别观察临床症状和测定肺功能FEV1,FVC ,PEF。结果 :国产组与进口组总有效率分别为 90 %和 85 % (P >0 .0 5 ) ;FEV1,FVC ,PEF改善率分别为 (45± 4 2 ) % ,(47± 5 0 ) % ,(2 9± 4 1) %和 (41± 36 ) % ,(45±4 2 ) % ,(2 9± 33) % (P >0 .0 5 )。副作用发生少 ,均为轻度 ,不影响治疗。结论 :国产与进口特布他林注射液疗效相仿 ,均能有效地改善哮喘和喘支炎病人的临床症状和肺通气功能     

塞曲司特治疗哮喘107例

目的:评价国产塞曲司特颗粒剂治疗支气管哮喘的疗效和安全性。方法:非急性发作期哮喘病人213例随机分为塞曲司特组(A组)107例,均口服塞曲司特80mg·d-1,疗程8wk;孟鲁司特组(B组)106例,均口服孟鲁司特10mg·d-1,疗程8wk。观察病人临床疗效、肺通气功能疗效和不良反应。结果:临床有效率A组73.8％(79/107),B组75.5％(80/106)。肺通气功能有效率A组55.1％(59/ 107),B组55.7％(59/106)。其中轻度和中度哮喘病人的临床疗效和肺功能改善均较重度哮喘病人更佳(p<0.05)。不良反应发生率A组5.6％(6/107),B组4.7％(5/106),未见严重不良反应。上述指标2组间比较差异均无显著意义(P>0.05)。结论:塞曲司特与孟鲁司特治疗支气管哮喘的疗效相似,是治疗支气管哮喘的安全、有效的新药。     

扎鲁司特联合舒利迭治疗儿童支气管哮喘临床疗效及对肺功能的影响

目的探讨扎鲁司特联合舒利迭对支气管哮喘患儿临床疗效及肺功能的影响。方法 80例哮喘患儿随机分为治疗组41例和对照组39例,对照组患儿吸入舒利迭;治疗组患儿在吸入舒利迭的基础上,口服白三烯拮抗剂扎鲁司特,2组疗程均为4周。评定治疗前后2组患儿临床疗效及肺功能改变情况。结果治疗组总有效率为90.2%,对照组总有效率为74.4%,2组差异有统计学意义(P<0.05);治疗后2组支气管哮喘患儿肺功能FEV1(实测值/预测值)、PEF(实测值/预测值)较治疗前均改善,差异有统计学意义(P<0.05);且治疗组支气管哮喘患儿肺功能FEV1(实/预)、PEF(实/预)改善较对照组明显,差异有统计学意义(P<0.05)。结论扎鲁司特与吸入糖皮质激素联合运用在改善哮喘患儿临床效果及肺功能的效果较单用吸入糖皮质激素更具优势,并且未见明显的不良反应。     

唾液中游离皮质醇和松果体素水平昼夜节律性变化与夜间哮喘相关性研究

目的　探讨唾液中游离皮质醇和松果体素水平昼夜节律性变化与夜间哮喘发病机制和昼夜肺功能变化的关系。方法　采用放射免疫分析方法测定 15例正常人和 15例夜间哮喘病人唾液中游离皮质醇和松果体素水平 ,哮喘病人中急性发作期 8例 ,缓解期 7例。 2 4h内按 12个时间点采集唾液样本 ,夜间取样时光照强度控制在 5 0lx之内。结果　 3组间游离皮质醇水平差异具有显著性 (P <0 0 1)。与对照组比较 ,急性发作期和缓解期病人游离皮质醇 2 4h平均水平均降低 (P <0 0 1) ;振幅减小 (P <0 0 5 ) ;峰值相位(acrophase)延迟 (P <0 0 1,P <0 0 5 )。 3组间游离松果体素水平差异亦具有显著性 (P <0 0 1)。与对照组比较 ,急性发作期和缓解期病人松果体素水平基线值 ,振幅和峰值皆降低(P <0 0 5orP <0 0 1) ;急性发作期峰值相位延迟 (P <0 0 5 )。凌晨 4点游离皮质醇水平分别与占FEV1预计值 %和占PEF预计值 %正相关 (r =0 5 3 ,P <0 0 5 ;r =0 5 5 ,P<0 0 5 ) ,游离松果体素水平与占PEF预计值 %呈正相关 (r=0 5 2 ,P <0 0 5 )。昼夜占PEF预计值 %差值和夜间出现症状或憋醒次数呈正相关 (r =0 62 5 ,P <0 0 5 )。结论　唾液中游离皮质醇和松果体素水平的昼夜节律性改变参与夜间哮喘的发病过程 ,且与病人     

氯沙坦与依那普利治疗高血压合并高尿酸血症各34例的比较

目的 :观察氯沙坦和依那普利对轻、中度原发性高血压合并高尿酸血症病人血尿酸代谢和降压疗效。方法 :6 8例轻、中度原发性高血压合并高尿酸血症病人分为 2组 ,氯沙坦组 34例 ,用氯沙坦 5 0mg ,po ,qd ,依那普利组 34例 ,用依那普利 10mg ,po ,qd ,均持续 4wk。结果 :wk 4末降压总有效率氯沙坦组 76 % ,依那普利组 79%。 2组疗效比较 ,P >0 .0 5。血尿酸水平在wk 4末氯沙坦组较治疗前下降 (12 5±s 4 0 ) μmol·L- 1,依那普利组下降(34± 38) μmol·L- 1,氯沙坦组和依那普利组降血尿酸总有效率为 74 %和 2 1% ,2组疗效比较 (P <0 .0 1)。结论 :氯沙坦不仅降压而且降低血尿酸水平。     

吸入呋塞米对支气管哮喘病人气道反应性的影响

目的 :探讨吸入呋塞米对支气管哮喘 (哮喘 )病人气道反应性的影响。方法 :缓解期哮喘病人4 0例 ,随机分为A ,B 2组 ,每组各 2 0例。试验分 2次隔日交叉吸入 0 .9%氯化钠注射液 4mL或呋塞米 4 0mg后予组胺吸入激发试验。结果 :2组病人吸入 0 .9%氯化钠注射液后的组胺PC2 0 FEV1差异无显著意义 (P >0 .0 5) ;吸入呋塞米后的组胺PC2 0 FEV1差异亦无显著意义 (P >0 .0 5) ;但 2组病人吸入呋塞米后的组胺PC2 0 FEV1均显著高于其吸入0 .9%氯化钠注射液后的组胺PC2 0 FEV1(均P <0 .0 5)。结论 :吸入呋塞米可抑制哮喘病人的气道高反应性。     

文拉法辛与舒必利辅助治疗精神分裂症阴性症状的比较

目的 :比较文拉法辛、舒必利辅助治疗精神分裂症阴性症状的疗效。方法 :随机设文拉法辛、舒必利治疗组各 30例。 2组原神经阻滞剂治疗方案不变。文拉法辛组给文拉法辛 2 5～ 50mg ,po ,tid ;舒必利组给舒必利 0 .1g ,po ,bid。均治疗 8wk。用SANS ,BPRS ,TESS评分观察。结果 :2组有效率分别为 80 % ,73% ,差别无显著意义 (P >0 .0 5)。 2组治疗后SANS及BPRS总分差值显示差别有非常显著意义 (P <0 .0 1)。组间比较SANS示wk 1,2 ,4差别有非常显著意义 (P <0 .0 1) ,wk 8差别无显著意义 (P >0 .0 5) ;BPRS示仅wk 1差别有非常显著意义 (P <0 .0 1)。TESS示 2组随着疗程延长 ,不良反应均示有减轻 ,但 2组间差别无显著意义 (P >0 .0 5)。结论 :文拉法辛辅助治疗精神分裂症阴性症状较舒必利起效早、疗效好、且安全。     

小剂量阿奇霉素联合沙美特罗替卡松气雾剂对慢性中度持续期哮喘患儿的疗效及依从性分析

目的 探究吸入小剂量阿奇霉素联合沙美特罗替卡松气雾剂对慢性中度持续期哮喘患儿的疗效及对其治疗依从性的影响。方法 选择2015年1月-2016年1月于郑州大学附属儿童医院进行治疗的98例慢性中度持续期哮喘患儿,按照随机数字表法将其分为观察组与对照组,每组各49例患者。对照组患儿给予沙美特罗替卡松气雾剂,1掀/次,2次/d;观察组患儿在对照组基础上增加阿奇霉素干混悬剂进行治疗,使用剂量为0.1 g/次,1次/d,连续服用3 d后停用4 d,而后继续。两组患儿治疗时间均为12周。对比两组患者治疗有效率,对比治疗前后两组患儿儿童哮喘控制测试（C-ACT）评分、哮喘用药依从性量表（MARS-A）评分、1秒用力呼气容积（FEV1）及最大呼气峰流速（PEF）,并对两组患儿治疗过程中不良反应发生率进行对比。结果 观察组患儿哮喘有效率为87.76%,对照组患儿有效率为65.31%,两组对比差异具有统计学意义（P<0.05）。治疗后两组患儿C-ACT及MARS-A得分均有所上升,对比治疗前差异具有统计学意义（P<0.05）;同时观察组患儿C-ACT及MARS-A得分均高于对照组,组间差异有统计学意义（P<0.05）。治疗后两组患儿FEV1及PEF均有提升,对比治疗前差异具有统计学意义（P<0.05）;同时观察组患者上述指标均高于对照组,组间差异有统计学意义（P<0.05）。两组不良反应发生率对比差异不具有统计学意义。结论 小剂量阿奇霉素联合沙美特罗替卡松气雾剂能够显著缓解慢性中度持续期哮喘患儿临床症状,改善患儿肺功能,同时具有较低的不良反应发生率,值得进行临床推广。     

血清和诱导痰嗜酸粒细胞阳离子蛋白在评价普米克治疗哮喘气道炎症中的作用

目的 :探讨血清、诱导痰嗜酸粒细胞阳离子蛋白 (ECP)与哮喘气道炎症及哮喘严重程度的关系。方法 :40例哮喘患者 (轻度 1 6例 ,中、重度 2 4例 )经普米克治疗前后分别行血清、诱导痰ECP以及肺功能第一秒用力呼气容量 (FEV1 )检测 ,并同时与正常人群血清、诱导痰ECP比较。结果 :哮喘患者治疗后血清、诱导痰ECP明显下降 (P <0 .0 1 ) ,肺功能FEV1 明显上升 (P <0 .0 1 ) ;哮喘患者治疗前 (发作期)血清、诱导痰ECP均明显高于正常人群 (P <0 .0 1 ) ,治疗后 (缓解期 )诱导痰ECP仍明显高于正常人群 (P <0 .0 1 ) ,血清ECP则稍高于正常人群 (P >0 .0 5 ) ;中、重度哮喘血清、诱导痰ECP明显高于轻度哮喘 (P <0 .0 5 ) ;血清、诱导痰ECP与FEV1 呈显著负相关 (r=-0 .48、-0 .5 0 ,P <0 .0 5 )。结论 :血清、诱导痰ECP可反映哮喘气道炎症以及严重程度 ,可用于哮喘气道炎症的研究以及指导治疗 ,诱导痰ECP比血清ECP更敏感。     

沙美特罗替卡松粉吸入剂治疗儿童哮喘243例

目的 :观察沙美特罗替卡松粉吸入剂治疗儿童哮喘前后的肺功能、临床疗效与不良反应。方法 :2 4 3例中、重度哮喘病儿给予沙美特罗替卡松粉(5 0 / 10 0 μg)吸入剂治疗 ,每次 1吸 ,早、晚各 1次 ,共 3mo ,同时进行用药前后第 1秒时间肺活量(FEV1)、最大呼气峰流速 (PEF)、PEF变异率 ,日间、夜间症状评分等动态监测。结果 :治疗前后FEV1,PEF ,PEF变异率 ,日间、夜间症状评分分别为 (1.1±s 0 .6 )L ,(2 .5± 0 .9)L·s- 1,(2 7± 5 ) % ,(3.4± 0 .7) ,(3.2± 0 .7)分和 (1.5± 0 .5 )L ,(3.9±1.2 )L·s- 1,(7± 3) % ,(0 .5± 0 .3) ,(0 .4± 0 .4 )分 ,差异有非常显著意义 (均P <0 .0 1) ,有效率达98.4 % ,未发现明显不良反应。结论 :沙美特罗替卡松粉吸入剂能显著改善哮喘病儿肺功能和明显缓解临床症状 ,临床应用安全。     

Pranlukast: a review of its use in the management of asthma

Pranlukast (Onon, Azlaire), is an orally administered, selective, competitive antagonist of the cysteinyl leukotrienes (LT) C(4), LTD(4) and LTE(4). It is indicated for the prophylactic treatment of chronic bronchial asthma in paediatric and adult patients. The efficacy of pranlukast 225mg twice daily in adults with mild to moderate asthma was demonstrated in double-blind, placebo- or azelastine-controlled studies of 4 or 8 weeks' duration. The drug at this dosage was superior to both comparators in improving mean attack scores and morning and/or evening peak expiratory flow rates, and decreasing the use of rescue bronchodilators (p < 0.05). In limited clinical studies, pranlukast 225mg twice daily appeared to be as effective as montelukast 10mg once daily and zafirlukast 40mg twice daily in adults with mild to moderate asthma. Tachyphylaxis was absent when the drug was administered for up to 4 years. In patients requiring high-dose inhaled corticosteroid therapy, pranlukast 225 mg twice daily plus a halved dosage of inhaled corticosteroid was as effective as the original dosage of inhaled corticosteroid. Pranlukast was also effective in patients with mild to severe asthma in a clinical practice setting. In a double-blind trial, greater improvements in most outcome measures were observed with pranlukast than with oxatomide in children and adolescents with asthma. In clinical trials, pranlukast was well tolerated in adult and paediatric patients with asthma, with an adverse event profile similar to that of placebo. Gastrointestinal events and hepatic function abnormalities were the most commonly reported adverse events. No clinically significant differences in adverse event profiles between pranlukast, zafirlukast or montelukast were shown in limited comparisons. Although Churg-Strauss syndrome has been noted in pranlukast recipients, a direct causal relationship is unlikely. CONCLUSIONS: Pranlukast is a well tolerated and effective preventative treatment in adult and paediatric patients with persistent asthma of all severities. In some patients, pranlukast may be beneficial when added to low-dose inhaled corticosteroids; it may also be a viable alternative to increasing inhaled corticosteroid dosages. The efficacy of pranlukast relative to placebo has been confirmed; its efficacy relative to other therapy awaits further investigation. Nonetheless, pranlukast is a useful therapeutic option (with as-required short-acting beta(2)-agonists), either as preventative monotherapy for the treatment of mild persistent asthma or in conjunction with inhaled corticosteroids in the management of moderate or severe persistent asthma.     

脾氨肽联合布地奈德治疗小儿支气管哮喘的疗效及其对血清CD4+、CD8+、IgE水平的影响

目的:研究脾氨肽联合布地奈德治疗小儿支气管哮喘的临床疗效及对免疫功能的影响。方法:选取我院2015年2月至2017年1月收治的支气管哮喘患儿102例,其中轻度哮喘25例,中度哮喘52例,重度哮喘25例,所有患儿按照随机数字法分为对照组和观察组各51例,对照组患儿给予雾化吸入布地奈德混悬液,观察组患儿在此基础上口服脾氨肽2 mg/d 治疗,比较两组患儿的治疗总有效率、住院时间、症状消失时间、肺功能变化情况、血清免疫细胞水平以及不良反应发生率。结果:观察组治疗总有效率(94.12%)高于对照组(78.3%,P<0.05),观察组临床症状消失时间和住院时间均短于对照组(P<0.01);治疗后观察组的FVC、FEV1、FEV1/FVC、CD4+、CD8+水平均高于对照组(P<0.01),IgE水平低于对照组(P<0.01);观察组总不良反应发生率低于对照组(P<0.05)。结论:脾氨肽联合布地奈德治疗小儿支气管哮喘的临床疗效显著,可有效改善肺功能状态,提高患儿免疫力,促进患儿早日康复,且安全性较高,值得临床推广。     

沙美特罗/氟替卡松联合噻托溴铵治疗重度支气管哮喘的临床观察

目的:探讨沙美特罗/氟替卡松联合噻托溴铵治疗重度支气管哮喘的临床疗效。方法:选取2010年1月—2011年12月收治的重度支气管哮喘患者共98例,以随机抽样法分为实验组和对照组各49例,其中实验组采用沙美特罗/氟替卡松联合噻托溴铵治疗,对照组仅用沙美特罗/氟替卡松治疗。结果:治疗后实验组患者的用力肺活量、最大呼气流量和最大呼气中段流量均明显高于对照组(P<0.05);2组患者的发作次数、住院次数及治疗费用比较,差异均具有统计学意义(P<0.05);2组患者的不良反应发生率比较,差异无统计学意义(P>0.05)。结论:采用沙美特罗/氟替卡松联合噻托溴铵治疗重度支气管哮喘,其疗效显著,不良反应少。     

Zafirlukast versus budesonide on bronchial reactivity in subjects with mild-persistent asthma

Asthma is one of the most common chronic diseases in children and adults. Recent studies have shown that in asthmatic patients treated with inhaled corticosteroids there is a better disease?s control when adding a second drug, than increasing the corticosteroid?s dose. The aim of this study has been to evaluate the effectiveness and tolerance of zafirlukast, a leukotriene receptor antagonist, versus budesonide in clinically steady patients with mild persistent bronchial asthma. We have enrolled 36 subjects non smokers, with mild persistent bronchial asthma and 12 healthy subjects as control group. At the beginning of this study and at the end of the treatment (8 weeks), all patients underwent complete clinical work-up, pulmonary function testing (FEV1, PEF and FVC) and methacholine challenge test. The patients were divided into 3 groups: group A) 20 mg of zafirlukast twice a day; group B) 400 mg of budesonide twice a day; group C) 20 mg of zafirlukast twice a day and 400 mg of budesonide twice a day. Basal FEV1 and PEF presented no significant statistical differences between control subjects and patients of group A, B and C. After eight weeks there were no significant changes for FEV1 and PEF among the three groups. After therapy a strong significant increase of PD20 was documented in group A (p<0.005), group B (p<0.001) and group C (p<0.005), respect to baseline values. The antileukotriene drugs could be taken as an alternative drug, or in association with low-dose inhaled corticosteroids, in patients with mild persistent asthma, both for their clinical effectiveness and their easy ingestion, which is confirmed in compliance studies on inhaled steroids.     

Combined salmeterol/fluticasone propionate versus fluticasone propionate alone in mild asthma : a placebo-controlled comparison

BACKGROUND AND OBJECTIVE: Combined therapy with inhaled corticosteroids (ICSs) and long-acting beta(2)-adrenoceptor agonists (LABAs) is the recommended approach for the treatment of patients with asthma that is uncontrolled on ICSs alone. Additional studies are needed to assess the safety and efficacy of combination treatment with ICSs and LABAs in patients with mild asthma. The aim of this study was to compare the efficacy and tolerability of once-daily salmeterol/fluticasone propionate combination (SFC) with once-daily fluticasone propionate (FP) over a 12-week treatment period in patients with mild persistent asthma. METHODS: This was a randomized, double-blind, placebo-controlled, parallel-group, multicentre study carried out in primary care or at a hospital outpatient department and included patients 12-79 years of age with mild persistent asthma (n = 458). After a 2-week run-in period, patients were randomized to receive SFC 50 microg/100 microg (n = 149), FP 100 microg (n = 154) or placebo (n = 155) once daily in the morning for 12 weeks. The primary efficacy endpoint was patient-recorded pre-dose mean morning peak expiratory flow (PEF). Other assessments included asthma symptom scores, use of rescue medication and investigator-recorded exacerbations. Lung function was measured and assessed during clinic visits. RESULTS: For the primary efficacy endpoint of mean change in morning PEF, SFC achieved significantly greater increases from baseline than both placebo (difference in adjusted means 23 L/min; 95% CI 15.0, 30.3; p < 0.001) and FP (difference in adjusted means 14 L/min; 95% CI 6.3, 21.7; p < 0.001). Compared with those who received FP, patients in the SFC group demonstrated significantly greater improvements in mean evening PEF (95% CI 11.7, 28.1; p < 0.001), forced expiratory volume in 1 second (95% CI 0.093, 0.257; p < 0.001), forced expiratory flow between 25% and 75% of forced vital capacity (95% CI 0.242, 0.617; p < 0.001), the percentage of symptom-free days (95% CI 0.34, 0.87; p = 0.011), and the percentage of rescue medication-free days (95% CI 0.34, 0.90; p = 0.018). During weeks 5-12, 52% of patients in the SFC group achieved 'well controlled' asthma, compared with 42% and 26% of patients in the FP and placebo groups, respectively. Only one patient (receiving placebo) had a severe asthma exacerbation during the study; the frequency of adverse events was similar across the three treatment groups. CONCLUSION: Once-daily SFC 50 microg/100 microg provided significantly greater improvements in lung function and in asthma symptoms than once-daily FP 100 microg alone in patients with mild persistent asthma. However, twice-daily treatment with either SFC or ICSs plus short acting beta(2)-adrenoceptor agonists could be required to achieve guideline-defined asthma control in some patients.     

屋尘螨免疫治疗儿童变应性鼻炎—哮喘综合征的临床疗效观察

目的 评价屋尘螨特异性免疫治疗对儿童变应性鼻炎—哮喘综合征的临床疗效和安全性.方法 将2010年6月—2012年6月年该院哮喘门诊44例变应性鼻炎—哮喘综合征患儿分为随机观察组（24例）和对照组（20例）,两组均采用哮喘和变应性鼻炎常规治疗,观察组联合屋尘螨特异性免疫治疗,所有患儿在治疗开始和治疗3、6、9及12个月进行呼气峰流速测定、哮喘症状及鼻部症状评分.结果 （1）治疗3个月,两组患儿的呼气峰流速值有所升高,哮喘症状及鼻部症状评分有所下降,但差异无统计学意义（P＞0.05）.（2）治疗6、9、12个月,观察组患儿的呼气峰流速值较对照组均明显升高,哮喘症状及鼻部症状评分均明显下降,差异均有统计学意义（P＜0.05）.（3）观察组少数患儿出现轻微不良反应,无严重不良反应发生.结论 屋尘螨特异性免疫治疗在维持治疗阶段能明显改善儿童变应性鼻炎—哮喘综合征的症状及肺功能,不良反应少.     

普米克令舒联合孟鲁司特钠在小儿支气管哮喘治疗中的应用效果

目的 研究吸入用布地奈德混悬液(商品名:普米克令舒)联合孟鲁司特钠在小儿支气管哮喘治疗中的应用效果.方法 80例小儿支气管哮喘患儿,随机分为对照组和观察组,每组40例.对照组单独采用普米克令舒进行治疗,观察组采用普米克令舒联合孟鲁司特钠进行治疗.对比两组患儿的肺功能指标[用力肺活量(FVC)、第1秒用力呼气容积(FEV...